2025 年 1 月 18 日，由北京市希思科临床肿瘤学研究基金会、杭州东方临床肿瘤研究中心共同主办的「2024 胃肠肿瘤年终大盘点」盛大召开。会议中揭榜 2024 胃肠领域十大临床热词，其中，肿瘤经典靶点人表皮生长因子受体 2（HER2）和抗 ...

Impact of combined resection of pancreas on long-term survival in patients with gastric cancer. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy ...

Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Taiwan needs to revamp research into stomach cancer and increase National Health Insurance (NHI) coverage for targeted ...

Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.

HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

in combination with other cancer therapies, has shown a significant tumor response in patients with HER2-positive advanced gastric cancer. The trial results were presented today at the 2025 ASCO ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

T-DXd is also approved for HER2-positive (IHC 3+ or ISH+) breast cancer, non-small cell lung cancer, gastric or gastroesophageal junction cancers, and carries a tumor-agnostic indication for HER2 ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...